In short
Clinical trials of Lumasiran are studying people with advanced primary hyperoxaluria type 1, a rare condition that causes high oxalate levels in the body. These studies evaluate how well the treatment works and measure changes in plasma oxalate in patients who are on dialysis and those who are not.
Key points
- Lumasiran clinical trial data here come from one Phase 3 study in advanced primary hyperoxaluria type 1. The trial was completed and enrolled 21 patients. It included two groups: patients not on dialysis and patients on dialysis. The main goal was to measure the percent change in plasma oxalate from baseline to Month 6. This helps show whether the study treatment changed oxalate levels in the blood over time.
Trial Overview
The available trial data describe one study of Lumasiran in people with advanced primary hyperoxaluria type 1 (PH1). The study was completed and focused on how treatment affected plasma oxalate, which is the amount of oxalate in the liquid part of the blood.
Who Participated
The trial enrolled patients with advanced PH1, a rare condition that causes too much oxalate to build up in the body. The study included 21 participants and separated them into two groups: people who were not on dialysis and people who were on dialysis.
This group split matters because dialysis means a person is already receiving a treatment that helps clean the blood when the kidneys do not work well.
Trial Design and Phase
This was an interventional study, which means researchers gave the study treatment and then measured the effect. It was a Phase 3 trial, which is a later stage of testing that usually looks at how well a treatment works in a patient group and continues to collect important study data.
The study title also identifies Lumasiran as ALN-GO1 and describes it as an investigational drug in this setting.
What Was Measured
The main outcome was the percent change in plasma oxalate from baseline to Month 6 in both study cohorts. Baseline means the starting point before treatment, and Month 6 means six months after the study began.
The brief summary says the study aimed to evaluate the effect of Lumasiran on plasma oxalate in patients who were not on dialysis and in those who were on dialysis. This shows that the trial was designed to see whether treatment changed oxalate levels in both groups.
What the Results Mean for Patients
For patients, this trial was mainly about whether Lumasiran could lower or change blood oxalate levels in advanced PH1. The study did not only look at one kind of patient; it included both dialysis and non-dialysis groups, which helps researchers understand how the trial treatment performs in different stages of kidney disease.
Because the study is completed, the trial question has already been tested in the planned group of patients.